Good decisions require good information
Find hidden gems and smart strategies from top experts when you join Seeking Alpha.
NUVL Nuvalent, Inc.Stock Price & Overview
$77.78
Charts
Quant Ranking
NUVL Analysis
NUVL News
Latest Headlines
Ratings Summary
People Also Follow
Similar to NUVL
ETFs Holding NUVL
NUVL Company Profile
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL Revenue
NUVL Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Profitability
Momentum
Capital Structure
Dividends
NUVL Ownership
NUVL Peers
Risk
Technicals
Investor Presentations
NUVL SEC Filings
Press Releases
NUVL Income Statement
NUVL Balance Sheet
NUVL Cash Flow Statement
NUVL Long Term Solvency
Discover More
You may be interested in: